書誌事項
- タイトル別名
-
- Combination chemotherapy with CHOP and monoclonal antibody for malignant lymphoma with a tumor of the cheek as the chief complaint: A case report.
この論文をさがす
抄録
Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen, which has been used for the therapy of B-cell non-Hodgkin lymphoma. It was approved by the Japanese Ministry of Health, Labour and Welfare in June 2001.<BR>We report a case of malignant lymphoma in the oral and maxillofacial region that was treated with rituximab and a combination of cyclophosphamide, doxorubicine, vincristin, and prednisolone (CHOP) and had an excellent response.<BR>The patient was a 62-year-old woman who had a swelling on the right side of the cheek. A computed tomographic scan revealed a mass measuring 33×30mm in the cheek with several swollen cervical lymph nodes. Biopsy of the cheek revealed lymphoid proliferation, consistent with malignant non-Hodgkin lymphoma (diffuse large Bcell lymphoma). Immunohistochemical staining was positive for CD20. The patient was therefore treated with rituximab and CHOP, and the tumor disappeared. One year 3 months have passed since treatment, and there is no evidence of recurrence.<BR>This is the first reported case of an excellent response of a malignant lymphoma in the oral and maxillofacial region to rituximab and CHOP in Japan.
収録刊行物
-
- 日本口腔外科学会雑誌
-
日本口腔外科学会雑誌 50 (4), 247-250, 2004
社団法人 日本口腔外科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206530513280
-
- NII論文ID
- 10018620220
-
- NII書誌ID
- AN00189163
-
- ISSN
- 21861579
- 00215163
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可